Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters.
about
Lipoic acid attenuates inflammation via cAMP and protein kinase A signaling.Lipoic Acid Pharmacokinetics at Baseline and 1 year in Secondary Progressive MS.Lipoic acid in secondary progressive MS: A randomized controlled pilot trial.The influence of nutritional factors on the prognosis of multiple sclerosis.Quantum-chemical investigation of the structure and the antioxidant properties of α-lipoic acid and its metabolitesSerum Dihydrolipoamide Dehydrogenase Is a Labile Enzyme.Lipoic acid attenuates innate immune infiltration and activation in the visceral adipose tissue of obese insulin resistant miceAnti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot studyLipoic acid decreases inflammation and confers neuroprotection in experimental autoimmune optic neuritis.A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease.Determination of lipoic acid in biological samples.Over-the-counter anti-oxidant therapies for use in multiple sclerosis: A systematic review.Tolerability in the elderly population of high-dose alpha lipoic acid: a potential antioxidant therapy for the eye.May diet and dietary supplements improve the wellness of multiple sclerosis patients? A molecular approach.α-Lipoic acid, functional fatty acid, as a novel therapeutic alternative for central nervous system diseases: A review.Lipoic Acid Stimulates cAMP Production in Healthy Control and Secondary Progressive MS Subjects.Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model.
P2860
Q33712137-A46AA81C-903A-47E9-8AF5-A88B88A1B6A8Q33848862-5D1AD8CF-B351-4C27-8B03-60F9ADC7F979Q33848866-9DDC58DB-1E03-4285-8FE3-8C6EBBDFA1BDQ34643392-CDF69670-6F09-41E0-86FB-CC14A9EF71BDQ36055890-2F2A223A-8DEA-4616-9FA0-0BD7D363D6BAQ36811202-65A815FF-2420-40AC-9CB4-15B032E1679DQ36849314-57D000BC-4587-4680-9C3F-135358EE5BADQ37107063-854FAF91-1F91-4FA5-B0CC-C5566A3FF980Q37180260-DC582838-FF04-477F-A405-A7AE4918D14EQ37456775-9E42F40A-DD77-4E9E-91EF-85831E5B5A22Q38566053-BF8AC29D-803B-44F6-8C78-811F3E8D4919Q38569263-A3C9ABAA-2842-40A5-BA2A-8D483F428B61Q38978374-DA618E86-34E2-44C8-A219-83B0FF41676EQ42704925-8628D1D0-DB10-4332-8943-1891748F5495Q46252229-BE585405-3058-4E81-AB11-C8E1CA538373Q47578122-9D66175B-DE47-40A7-82BA-2902206D7956Q55451223-7488546B-5B16-4AB8-94FE-7C14742AAF0A
P2860
Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Pharmacokinetic study of lipoi ...... an pharmacokinetic parameters.
@ast
Pharmacokinetic study of lipoi ...... an pharmacokinetic parameters.
@en
type
label
Pharmacokinetic study of lipoi ...... an pharmacokinetic parameters.
@ast
Pharmacokinetic study of lipoi ...... an pharmacokinetic parameters.
@en
prefLabel
Pharmacokinetic study of lipoi ...... an pharmacokinetic parameters.
@ast
Pharmacokinetic study of lipoi ...... an pharmacokinetic parameters.
@en
P2093
P2860
P356
P1476
Pharmacokinetic study of lipoi ...... an pharmacokinetic parameters.
@en
P2093
Dennis N Bourdette
Dennis R Koop
Gail H Marracci
Lauren E Stuber
Lilia Alvarez
Lynne Shinto
Myrna Y Munar
Vijayshree Yadav
P2860
P304
P356
10.1177/1352458509359722
P577
2010-02-11T00:00:00Z